Compare Cassava Sciences Inc (FLNA) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while GraniteShares 2x Long NVDA Daily ETF trades at $31.87. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | NVDL | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $43.02 |
52-Week Low | $1.09 | $21.76 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $31.88, down 3.89% on the day, reflecting high volatility tied to its 2x leveraged exposure to NVIDIA. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI suggests potential overbought conditions. Recent stock splits on June 25-26, 2026, aim to improve liquidity. The ETF has delivered significant returns year-to-date (up 12.66% as of June 8, 2026, per 24/7 Wall Street) but remains vulnerable to sharp daily moves in NVIDIA.
The outlook for NVDL hinges entirely on NVIDIA's performance, offering amplified gains during AI-driven rallies but exposing investors to compounded losses during downturns. Key risks include daily reset mechanics, which can erode value in volatile markets, and dependence on a single stock. Investors seeking leveraged NVIDIA exposure must tolerate extreme volatility and monitor NVIDIA's earnings closely. The ETF suits aggressive traders betting on continued AI momentum but is unsuitable for long-term, risk-averse portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
